Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-348 in Hypertensive Patients With Dyslipidemia
NCT04388215Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CKD-348 in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Change rate from baseline in Low Density Lipoprotein-C at 8 weeks and Change from baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Status: unknown.
02
Drugs
CKD-348
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04388215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388215.